Biotechnology Letters

, Volume 40, Issue 11–12, pp 1459–1466 | Cite as

Anti-CD37 targeted immunotherapy of B-Cell malignancies

  • Zahra Payandeh
  • Effat Noori
  • Bahman Khalesi
  • Maysam Mard-Soltani
  • Jalal Abdolalizadeh
  • Saeed KhaliliEmail author


CD37 is a member of tetra-spanning superfamily (characterized by their four transmembrane domains). It is one of the specific proteins for normal and malignant mature B cells. Anti CD37 monoclonal antibodies are reported to improve the overall survival in CLL. These therapeutics will increase the efficacy and reduce the toxicity in patients with both newly diagnosed and relapsed and refractory disease. Recent clinical trials have shown promising outcomes for these agents, administered both as monotherapy and in combination with standard chemotherapeutics. Long-term follow-up of combination regimens has even raised the question of whether the patients with CLL could be treated with intensive chemo-immunotherapy. In the present study, CD37 is introduced as an appealing target to treat B cell malignancies. The anti-CD37 antibodies as one of the most successful therapeutics against CD37 are introduced and the clinical outcomes of their exploitation are explained.


CD37 Chronic lymphocytic leukemia Monoclonal antibody Non-Hodgkin lymphoma Otlertuzumab TRU-016 



The authors thank Shahid Rajaee Teacher Training University and Zanjan University of Medical Sciences for support to conduct this work.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

This article does not contain any studies with human participants or animals performed by any of the authors.


  1. Betrian S, Ysebaert L, Heider K, Delord J, Fournié J, Quillet-Mary A (2016) Idelalisib improves CD37 antibody BI 836826 cytotoxicity against chemo-resistant/relapse-initiating CLL cells: a rationale for combination treatment. Blood Cancer J 6:e496CrossRefGoogle Scholar
  2. Caravella J, Lugovskoy A (2010) Design of next-generation protein therapeutics. Curr Opin Chem Biol 14:520–528CrossRefGoogle Scholar
  3. Carter PJ (2006) Potent antibody therapeutics by design. Nat Rev Immunol 6:343CrossRefGoogle Scholar
  4. Deckert J et al (2013) A novel anti-CD37 antibody-drug conjugate with multiple anti-tumor mechanisms for the treatment of B-cell malignancies. Blood 122:3500–3510CrossRefGoogle Scholar
  5. Deckert J et al (2015) IMGN529, a novel antibody-drug conjugate (ADC) targeting CD37 shows synergistic activity with rituximab in non-Hodgkin lymphoma (NHL) models. Blood 126:1548Google Scholar
  6. Eccles SA (2001) Monoclonal antibodies targeting cancer: magic bullets or just the trigger? Breast Cancer Res 3:86CrossRefGoogle Scholar
  7. Gartlan KH et al (2013) Tetraspanin CD37 contributes to the initiation of cellular immunity by promoting dendritic cell migration. Eur J Immunol 43:1208–1219CrossRefGoogle Scholar
  8. Gopal AK et al (2014) Phase 1b study of otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR™ therapeutic protein, in combination with rituximab and bendamustine in relapsed indolent lymphoma patients. Invest New Drugs 32:1213–1225CrossRefGoogle Scholar
  9. Heider K-H et al (2011) A novel Fc-engineered monoclonal antibody to CD37 with enhanced ADCC and high proapoptotic activity for treatment of B-cell malignancies. Blood 118:4159–4168CrossRefGoogle Scholar
  10. Hellman A et al (2013) Phase 2 study of otlertuzumab (TRU-016), an anti-CD37 ADAPTIRTM protein, in combination with bendamustine vs bendamustine alone in patients with relapsed chronic lymphocytic leukemia (CLL). Blood 122:2860Google Scholar
  11. Hemler ME, Mannion BA, Barditchevski F (1996) Association of TM4SF proteins with integrins: relevance to cancer. Biochim Biophys Acta 1287:67–71PubMedGoogle Scholar
  12. Jin L, Cambier JC (2012) SMIP-016 in action: CD37 as a death receptor. Cancer Cell 21:597–598CrossRefGoogle Scholar
  13. Knobeloch K-P et al (2004) A regulatory role for CD37 in T cell. J Immunol 172:2953–2961CrossRefGoogle Scholar
  14. Kolstad A (2016) Efficacy and safety results of Betalutin®(177 Lu-DOTA-HH1) in a phase 1/2 study of patients with non-hodgkin B-cell lymphoma (NHL). Platelets 10:100Google Scholar
  15. Krause G et al (2012) Action of novel CD37 antibodies on chronic lymphocytic leukemia cells. Leukemia 26:546CrossRefGoogle Scholar
  16. Lapalombella R et al (2012) Tetraspanin CD37 directly mediates transduction of survival and apoptotic signals. Cancer Cell 21:694–708CrossRefGoogle Scholar
  17. Nelson AL, Dhimolea E, Reichert JM (2010) Development trends for human monoclonal antibody therapeutics. Nat Rev Drug Discov 9:767CrossRefGoogle Scholar
  18. Payandeh Z, Rajabibazl M, Mortazavi Y, Rahimpour A, Taromchi AH (2018a) Ofatumumab monoclonal antibody affinity maturation through in silico modeling. Iran Biomed J 22:180PubMedPubMedCentralGoogle Scholar
  19. Payandeh Z, Rajabibazl M, Mortazavi Y, Rahimpour A, Taromchi AH, Dastmalchi S (2018b) Affinity maturation and characterization of the ofatumumab monoclonal antibody. J Cell Biochem. CrossRefPubMedGoogle Scholar
  20. Pereira DS et al (2015) AGS67E, an anti-CD37 monomethyl auristatin E antibody drug conjugate as a potential therapeutic for B/T-cell malignancies and AML: a new role for CD37 in AML. Mol Cancer Ther. CrossRefPubMedPubMedCentralGoogle Scholar
  21. Plas DR et al (1996) Direct regulation of ZAP-70 by SHP-1 in T cell antigen receptor signaling. Science 272:1173–1176CrossRefGoogle Scholar
  22. Reichert JM (2012) Marketed therapeutic antibodies compendium, vol 3. Taylor & Francis, Abingdon, pp 413–415Google Scholar
  23. Reichert JM (2014) Antibodies to watch in 2014: mid-year update, vol 4. Taylor & Francis, Abingdon, pp 799–802Google Scholar
  24. Robak T, Robak P (2014) Anti-CD37 antibodies for chronic lymphocytic leukemia. Expert Opin Biol Therapy 14:651–661CrossRefGoogle Scholar
  25. Rosenwald A et al (2002) The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 346:1937–1947CrossRefGoogle Scholar
  26. Schwartz-Albiez R, Dörken B, Hofmann W, Moldenhauer G (1988) The B cell-associated CD37 antigen (gp40-52). Structure and subcellular expression of an extensively glycosylated glycoprotein. J Immunol 140:905–914PubMedGoogle Scholar
  27. Sliwkowski MX, Mellman I (2013) Antibody therapeutics in cancer. Science 341:1192–1198CrossRefGoogle Scholar
  28. Stathis A et al (2014a) A phase I study of IMGN529, an antibody-drug conjugate (ADC) targeting CD37, in adult patients with relapsed or refractory b-cell non-hodgkin’s lymphoma (NHL). Blood 124:1760Google Scholar
  29. Stathis A et al (2014b) Preliminary findings from a phase I, multicenter, open-label study of the anti-CD37 antibody-drug conjugate (ADC), IMGN529, in adult patients with relapsed or refractory non-Hodgkin lymphoma (NHL). J Clin Oncol 35(15):8526Google Scholar
  30. Tarrant JM, Robb L, van Spriel AB, Wright MD (2003) Tetraspanins: molecular organisers of the leukocyte surface. Trends Immunol 24:610–617CrossRefGoogle Scholar
  31. Tomlinson MG, Wright MD (1996) Characterisation of mouse CD37: cDNA and genomic cloning. Mol Immunol 33:867–872CrossRefGoogle Scholar
  32. Veenbergen S, van Spriel AB (2011) Tetraspanins in the immune response against cancer. Immunol Lett 138:129–136CrossRefGoogle Scholar
  33. Virtaneva KI, Angelisová P, Baumruker T, Hořejší V, Nevanlinna H, Schröder J (1993) The genes for CD37, CD53, and R2, all members of a novel gene family, are located on different chromosomes. Immunogenetics 37:461–465CrossRefGoogle Scholar
  34. Walsh G (2014) Biopharmaceutical benchmarks 2014. Nat Biotechnol 32:992CrossRefGoogle Scholar
  35. Wu C, Sun M, Liu L, Zhou GW (2003) The function of the protein tyrosine phosphatase SHP-1 in cancer. Gene 306:1–12CrossRefGoogle Scholar
  36. Xu-Monette ZY et al (2016) Assessment of CD37 B-cell antigen and cell-of-origin significantly improves risk prediction in diffuse large B-cell lymphoma. Blood. CrossRefPubMedPubMedCentralGoogle Scholar
  37. Zapata PDO et al (2002) Autocrine regulation of human prostate carcinoma cell proliferation by somatostatin through the modulation of the SH2 domain containing protein tyrosine phosphatase (SHP)-1. J Clin Endocrinol Metab 87:915–926CrossRefGoogle Scholar
  38. Zhao X et al (2007) Targeting CD37-positive lymphoid malignancies with a novel engineered small modular immunopharmaceutical. Blood 110:2569–2577CrossRefGoogle Scholar

Copyright information

© Springer Nature B.V. 2018

Authors and Affiliations

  • Zahra Payandeh
    • 1
  • Effat Noori
    • 2
  • Bahman Khalesi
    • 3
  • Maysam Mard-Soltani
    • 4
  • Jalal Abdolalizadeh
    • 5
  • Saeed Khalili
    • 6
    Email author
  1. 1.Department of Medical Biotechnology and Nanotechnology, Faculty of MedicineZanjan University of Medical SciencesZanjanIran
  2. 2.Cellular and Molecular Biology Research CenterShahid Beheshti University of Medical SciencesTehranIran
  3. 3.Department of Research and Production of Poultry Viral Vaccine, Razi Vaccine and Serum Research InstituteAgricultural Research Education and Extension Organization (AREEO)KarajIran
  4. 4.Department of Clinical Biochemistry, Faculty of Medical SciencesDezful University of Medical SciencesDezfulIran
  5. 5.Drug Applied Research Center, Faculty of MedicineTabriz University of Medical SciencesTabrizIran
  6. 6.Department of Biology SciencesShahid Rajaee Teacher Training UniversityTehranIran

Personalised recommendations